Xencor, based in Monrovia, United States, is dedicated to developing advanced monoclonal antibody therapies to treat cancer, asthma, and autoimmune disorders. The company's mission is to engineer superior antibody and cytokine therapeutics from the ground up, aiming to improve patient outcomes in these critical areas. Xencor's innovative approach focuses on creating highly effective treatments that address significant unmet medical needs.
Xencor has achieved notable success in advancing its therapeutic candidates through various stages of clinical development. The company's pioneering work in antibody engineering has garnered attention and support from leading investors and collaborators in the biotech industry. By leveraging its proprietary technology platforms, Xencor continues to make a substantial impact on the treatment landscape for serious diseases, enhancing the quality of life for patients worldwide.
